Author’s response to reviews

Title: Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT)) - Study protocol for a national, multicentre randomized controlled trial

Authors:

Knut Jørgen Labori (kjlabori@gmail.com;uxknab@ous-hf.no)
Kristoffer Lassen (krlass@ous-hf.no)
Dag Hoem (dag.hoem@helse-bergen.no)
Jon Grønbech (jon.e.gronbech@ntnu.no)
Jon Søreide (jonarne.soreide@uib.no)
Kim Mortensen (Kim.Erlend.Mortensen@unn.no)
Rune Smaaland (rune.smaaland@sus.no)
Halfdan Sørbye (halfdan.sorbye@helse-bergen.no)
Caroline Verbeke (c.s.verbeke@medisin.uio.no)
Svein Dueland (svedue@ous-hf.no)

Version: 1 Date: 20 May 2017

Author’s response to reviews:

Dear Editor BMC Surg

Copies of all ethical approval have now been forwarded to "BMCSeriesEditorial@biomedcentral.com" for your records. The documents are not in English, so relevant parts have been translated in a letter endorsed and signed by a contactable person at Oslo University Hospital.
Kind regards

Knut Jørgen Labori
Senior consultant surgeon, PhD
Head Unit of Pancreatic and Neuroendocrine Surgery
Department of Hepato-Pancreato-Biliary Surgery
Oslo University Hospital
Oslo, Norway